+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibiotic Resistance Market - Global Forecast 2026-2032- Product Image
Antibiotic Resistance Market - Global Forecast 2026-2032- Product Image
Sale

Antibiotic Resistance Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6014952
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibiotic Resistance Market is projected to reach USD 8.45 Billion in 2026. It is expected to continue growing at a CAGR of 6.32%, reaching USD 12.23 Billion by 2032.

Antibiotic Resistance: Executive Overview

Antibiotic resistance occurs when bacteria evolve so that medicines designed to kill or inhibit them become less effective. It is driven by antibiotic use and misuse in human health, animal production, and environmental settings, and is amplified by inadequate infection prevention, poor sanitation, limited diagnostics, and gaps in access to appropriate treatment. The resulting burden includes harder-to-treat infections, longer hospital stays, greater treatment complexity, and increased pressure on health systems. Effective responses require coordinated action across human, animal, food, and environmental health under a One Health framework.

How Stewardship and Prevention Are Reshaping the Response

The response is shifting from reliance on new antibiotics toward a broader resilience model that combines antimicrobial stewardship, vaccination, infection prevention and control, surveillance, diagnostic capacity, and dependable access to quality-assured medicines. Hospitals and public-health agencies are strengthening prescribing protocols, laboratory networks, and outbreak detection, while food and agriculture stakeholders are working to reduce unnecessary antimicrobial use. Policy attention is also moving toward sustainable innovation incentives, stronger regulation of antibiotic sales, and improved monitoring of resistance and consumption across sectors.

Artificial Intelligence Strengthens Detection and Decision Support

Artificial intelligence can support antibiotic-resistance control by identifying resistance patterns in laboratory and clinical data, improving triage, assisting antimicrobial selection, and accelerating analysis of genomic surveillance. Machine-learning tools may help detect outbreaks earlier and identify patients at elevated risk, but their value depends on representative data, interoperable systems, validation in routine care, and human oversight. Bias, privacy, cybersecurity, explainability, and the risk of automating inappropriate prescribing remain material concerns. AI should therefore augment trained clinicians and microbiologists rather than replace stewardship governance.

Regional Priorities Across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific

North America generally benefits from advanced laboratory and surveillance capabilities, but must address resistant infections in hospitals, long-term care, and communities while preserving antibiotic access. Latin America faces uneven diagnostic capacity, fragmented surveillance, and variable regulation, making infection prevention and affordable quality-assured treatment central priorities. Europe has established cross-border surveillance and stewardship structures, yet resistance remains heterogeneous among countries and healthcare settings. The Middle East requires stronger laboratory networks, infection-control implementation, and coordinated responses across highly mobile populations. Africa’s priorities include reliable diagnostics, essential-medicine access, sanitation, vaccination, and surveillance coverage. Asia-Pacific combines major innovation capacity with substantial differences in healthcare access, antimicrobial-use practices, and regulatory enforcement, requiring locally adapted One Health programs.

Group-Level Coordination Through ASEAN, BRICS, the European Union, G7, GCC, and NATO

ASEAN cooperation can improve cross-border surveillance, laboratory standards, and stewardship while accounting for varied health-system capacity. BRICS members can support shared research, diagnostic development, and technical collaboration, particularly where resistance patterns and access challenges overlap. The European Union benefits from coordinated surveillance, common policy mechanisms, and joint preparedness, while continued implementation across member states remains important. The G7 can advance financing, research incentives, supply-chain resilience, and global technical standards. GCC collaboration can strengthen regional infection control, laboratory capacity, and preparedness for cross-border transmission. NATO’s health-security role is relevant to medical readiness, supply continuity, and interoperable surveillance during crises, without substituting for civilian public-health systems.

Country Priorities From Australia to the United States

Australia can build on national stewardship and surveillance by sustaining rural, hospital, and agricultural coverage. Brazil should continue expanding integrated surveillance, laboratory access, and stewardship across a diverse health system. Canada’s priorities include coordinated provincial surveillance, antimicrobial stewardship, and Indigenous and remote-community access. China can strengthen prescription oversight, hospital stewardship, diagnostics, and agricultural monitoring at scale. France, Germany, Italy, and Spain can reinforce implementation of European and national action plans, with attention to hospitals, community care, and food production. India requires continued investment in diagnostics, sanitation, infection prevention, and enforcement against inappropriate access while preserving access to essential treatment. Japan and South Korea can deepen hospital stewardship, ageing-population preparedness, and laboratory interoperability. Mexico can improve community prescribing oversight, surveillance integration, and infection prevention. Russia faces the need for reliable surveillance, laboratory capacity, stewardship, and quality-assured access across geographically diverse settings. The United Kingdom can sustain coordinated surveillance, prevention, and innovation policies. The United States can further integrate hospital, community, animal, and environmental data while strengthening stewardship and innovation incentives.

Actions for Industry and Health-System Leaders

Leaders should establish measurable stewardship targets, link prescribing decisions to timely diagnostics, and ensure that infection-prevention programs receive operational funding. Organizations should integrate laboratory, pharmacy, clinical, agricultural, and environmental data under clear governance; audit antibiotic use and resistance trends; and use findings to guide local interventions. Supply-chain planning should protect the availability and quality of essential antibiotics while reducing shortages that encourage inappropriate substitution. Investment priorities should include vaccines, rapid diagnostics, alternatives to antibiotics, and carefully validated digital and AI tools. Cross-sector partnerships, workforce training, transparent reporting, and equitable access should be treated as core performance responsibilities rather than optional initiatives.

Research Methodology for an Evidence-Based Assessment

This executive summary uses a structured One Health assessment framework focused on documented drivers, impacts, interventions, and implementation conditions. Evidence should be triangulated across peer-reviewed research, national and international surveillance systems, public-health guidance, regulatory records, antimicrobial-consumption data, laboratory findings, and sector-specific reports. Findings should be compared by geography and population group, with attention to differences in testing coverage, reporting practices, healthcare access, prescribing behavior, and data quality. Claims should be retained only when supported by credible sources, and uncertainty should be stated explicitly. The assessment excludes market estimates, market sizing, market shares, and forecasts.

Conclusion: Coordinated Action Is the Defining Requirement

Antibiotic resistance is a cross-border and cross-sector threat whose trajectory depends on everyday decisions in healthcare, agriculture, public health, and the environment. No single intervention is sufficient: prevention, vaccination, diagnostics, responsible prescribing, surveillance, treatment access, innovation, and resilient supply chains must operate together. Regional and country differences require tailored implementation, while shared standards and data enable cooperation. Sustained leadership, accountable measurement, and equitable investment can reduce avoidable infections and preserve the effectiveness of antibiotics for future patients.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antibiotic Resistance Market, by Offering
7.1. Introduction
7.2. Combination Therapies
7.3. Drugs
7.3.1. Aminoglycosides
7.3.2. Beta-Lactams
7.3.3. Fluoroquinolones
7.3.4. Glycopeptides
7.3.5. Macrolides
7.3.6. Oxazolidinones
7.3.7. Polymyxins
7.3.8. Sulfonamides
7.3.9. Tetracyclines
7.4. Immunomodulators
7.5. Monoclonal Antibodies
7.6. Phage Therapy
8. Antibiotic Resistance Market, by Pathogen Type
8.1. Introduction
8.2. Acinetobacter Paumannii (A. baumannii)
8.3. Escherichia Coli (E. coli)
8.4. Klebsiella Pneumoniae (K. pneumoniae)
8.5. Pseudomonas Aeruginosa (P. aeruginosa)
8.6. Staphylococcus Aureus (S. aureus)
8.7. Streptococcus Pneumonia (S. pneumoniae)
9. Antibiotic Resistance Market, by Infection Type
9.1. Introduction
9.2. Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
9.3. Bloodstream Infections (BSI)
9.4. Clostridioides difficile Infection (CDI)
9.5. Community-Acquired Bacterial Pneumonia (CABP)
9.6. Complicated Urinary Tract Infections (cUTI)
10. Antibiotic Resistance Market, by End Use
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Diagnostic Laboratories
10.4. Hospitals & Clinics
10.5. Research Institutes
11. Antibiotic Resistance Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Antibiotic Resistance Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Antibiotic Resistance Market, by Country
13.1. Introduction
13.2. United States
13.3. China
13.4. Germany
13.5. India
13.6. United Kingdom
13.7. Japan
13.8. Canada
13.9. France
13.10. Brazil
13.11. Italy
13.12. Australia
13.13. Mexico
13.14. Spain
13.15. South Korea
13.16. Russia
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. AbbVie Inc.
15.3. ANTABIO
15.4. AstraZeneca plc
15.5. Basilea Pharmaceutica Ltd
15.6. Bayer AG
15.7. bioMérieux S.A.
15.8. BioVersys AG
15.9. C.H. Boehringer Sohn AG & Co. KG
15.10. Cipla Limited
15.11. Cumberland Pharmaceuticals
15.12. Day Zero Diagnostics Inc.
15.13. Eli Lilly and Company
15.14. F. Hoffmann-La Roche Ltd
15.15. GlaxoSmithKline plc
15.16. Glox Theraputics Ltd
15.17. Hikma Pharmaceuticals PLC
15.18. Innoviva, Inc.
15.19. Johnson & Johnson Services, Inc.
15.20. Melinta Therapeutics LLC
15.21. Merck & Co., Inc.
15.22. Novo Holdings A/S
15.23. Paratek Pharmaceuticals, Inc.
15.24. Pfizer Inc.
15.25. Sandoz AG
15.26. Seres Therapeutics, Inc.
15.27. Shionogi & Co., Ltd.
15.28. Teva Pharmaceutical Industries Ltd.
15.29. Theravance Biopharma, Inc.
15.30. Wockhardt
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Antibiotic Resistance Market, Years Considered for the Study
FIGURE 2. Global Antibiotic Resistance Market, Research Design
FIGURE 3. Global Antibiotic Resistance Market, Research Framework
FIGURE 4. Global Antibiotic Resistance Market, Data Triangulation
FIGURE 5. Global Antibiotic Resistance Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Antibiotic Resistance Market Size, by Offering, 2025 vs 2032 (%)
FIGURE 7. Global Antibiotic Resistance Market Size, by Offering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Antibiotic Resistance Market Size, by Pathogen Type, 2025 vs 2032 (%)
FIGURE 9. Global Antibiotic Resistance Market Size, by Pathogen Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Antibiotic Resistance Market Size, by Infection Type, 2025 vs 2032 (%)
FIGURE 11. Global Antibiotic Resistance Market Size, by Infection Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Antibiotic Resistance Market Size, by End Use, 2025 vs 2032 (%)
FIGURE 13. Global Antibiotic Resistance Market Size, by End Use, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Antibiotic Resistance Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Antibiotic Resistance Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Antibiotic Resistance Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Antibiotic Resistance Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Antibiotic Resistance Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Antibiotic Resistance Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Antibiotic Resistance Market Segmentation & Coverage
TABLE 2. Global Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 3. Global Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 4. Global Combination Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Combination Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Combination Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Aminoglycosides Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Aminoglycosides Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Aminoglycosides Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Beta-Lactams Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Beta-Lactams Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Beta-Lactams Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Fluoroquinolones Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Fluoroquinolones Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Fluoroquinolones Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Glycopeptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Glycopeptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Glycopeptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Macrolides Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Macrolides Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Macrolides Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Oxazolidinones Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Oxazolidinones Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Oxazolidinones Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Polymyxins Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Polymyxins Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Polymyxins Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Sulfonamides Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Sulfonamides Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Sulfonamides Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Tetracyclines Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Tetracyclines Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Tetracyclines Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Immunomodulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Immunomodulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Immunomodulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Phage Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Phage Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Phage Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 47. Global Acinetobacter Paumannii (A. baumannii) Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Acinetobacter Paumannii (A. baumannii) Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Acinetobacter Paumannii (A. baumannii) Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Escherichia Coli (E. coli) Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Escherichia Coli (E. coli) Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Escherichia Coli (E. coli) Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Klebsiella Pneumoniae (K. pneumoniae) Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Klebsiella Pneumoniae (K. pneumoniae) Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Klebsiella Pneumoniae (K. pneumoniae) Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Pseudomonas Aeruginosa (P. aeruginosa) Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Pseudomonas Aeruginosa (P. aeruginosa) Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Pseudomonas Aeruginosa (P. aeruginosa) Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Staphylococcus Aureus (S. aureus) Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Staphylococcus Aureus (S. aureus) Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Staphylococcus Aureus (S. aureus) Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Streptococcus Pneumonia (S. pneumoniae) Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Streptococcus Pneumonia (S. pneumoniae) Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Streptococcus Pneumonia (S. pneumoniae) Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 66. Global Acute Bacterial Skin & Skin Structure Infections (ABSSSI) Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Acute Bacterial Skin & Skin Structure Infections (ABSSSI) Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Acute Bacterial Skin & Skin Structure Infections (ABSSSI) Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Bloodstream Infections (BSI) Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Bloodstream Infections (BSI) Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Bloodstream Infections (BSI) Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Clostridioides difficile Infection (CDI) Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Clostridioides difficile Infection (CDI) Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Clostridioides difficile Infection (CDI) Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Community-Acquired Bacterial Pneumonia (CABP) Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Community-Acquired Bacterial Pneumonia (CABP) Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Community-Acquired Bacterial Pneumonia (CABP) Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Complicated Urinary Tract Infections (cUTI) Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Complicated Urinary Tract Infections (cUTI) Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Complicated Urinary Tract Infections (cUTI) Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 82. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 101. North America Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. North America Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 103. North America Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 104. North America Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 105. North America Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 106. North America Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 107. Latin America Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Latin America Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 109. Latin America Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 110. Latin America Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 111. Latin America Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 112. Latin America Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 113. Europe Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Europe Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 115. Europe Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 116. Europe Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 117. Europe Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 118. Europe Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 119. Middle East Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Middle East Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 121. Middle East Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 122. Middle East Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 123. Middle East Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 124. Middle East Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 125. Africa Antibiotic Resistance Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Africa Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 127. Africa Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 128. Africa Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 129. Africa Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 130. Africa Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 131. Global Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. ASEAN Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. ASEAN Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 134. ASEAN Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 135. ASEAN Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 136. ASEAN Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 137. ASEAN Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 138. GCC Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. GCC Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 140. GCC Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 141. GCC Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 142. GCC Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 143. GCC Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 144. European Union Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. European Union Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 146. European Union Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 147. European Union Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 148. European Union Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 149. European Union Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 150. BRICS Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. BRICS Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 152. BRICS Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 153. BRICS Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 154. BRICS Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 155. BRICS Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 156. G7 Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. G7 Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 158. G7 Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 159. G7 Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 160. G7 Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 161. G7 Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 162. NATO Antibiotic Resistance Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. NATO Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 164. NATO Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 165. NATO Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 166. NATO Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 167. NATO Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 168. Global Antibiotic Resistance Market Size, by Country, 2017-2032 (USD Million)
TABLE 169. United States Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 170. United States Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 171. United States Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 172. United States Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 173. United States Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 174. United States Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 175. China Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 176. China Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 177. China Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 178. China Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 179. China Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 180. China Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 181. Germany Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 182. Germany Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 183. Germany Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 184. Germany Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 185. Germany Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 186. Germany Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 187. India Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 188. India Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 189. India Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 190. India Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 191. India Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 192. India Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 193. United Kingdom Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 194. United Kingdom Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 195. United Kingdom Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 196. United Kingdom Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 197. United Kingdom Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 198. United Kingdom Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 199. Japan Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 200. Japan Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 201. Japan Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 202. Japan Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 203. Japan Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 204. Japan Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 205. Canada Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 206. Canada Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 207. Canada Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 208. Canada Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 209. Canada Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 210. Canada Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 211. France Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 212. France Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 213. France Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 214. France Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 215. France Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 216. France Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 217. Brazil Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 218. Brazil Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 219. Brazil Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 220. Brazil Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 221. Brazil Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 222. Brazil Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 223. Italy Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 224. Italy Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 225. Italy Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 226. Italy Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 227. Italy Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 228. Italy Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 229. Australia Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 230. Australia Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 231. Australia Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 232. Australia Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 233. Australia Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 234. Australia Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 235. Mexico Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 236. Mexico Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 237. Mexico Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 238. Mexico Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 239. Mexico Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 240. Mexico Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 241. Spain Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 242. Spain Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 243. Spain Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 244. Spain Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 245. Spain Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 246. Spain Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 247. South Korea Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 248. South Korea Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 249. South Korea Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 250. South Korea Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 251. South Korea Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 252. South Korea Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 253. Russia Antibiotic Resistance Market Size, 2017-2032 (USD Million)
TABLE 254. Russia Antibiotic Resistance Market Size, by Offering, 2017-2032 (USD Million)
TABLE 255. Russia Antibiotic Resistance Market Size, by Drugs, 2017-2032 (USD Million)
TABLE 256. Russia Antibiotic Resistance Market Size, by Pathogen Type, 2017-2032 (USD Million)
TABLE 257. Russia Antibiotic Resistance Market Size, by Infection Type, 2017-2032 (USD Million)
TABLE 258. Russia Antibiotic Resistance Market Size, by End Use, 2017-2032 (USD Million)
TABLE 259. Global Antibiotic Resistance Market Share, by Key Player, 2025
TABLE 260. Global Antibiotic Resistance Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • ANTABIO
  • AstraZeneca plc
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • bioMérieux S.A.
  • BioVersys AG
  • C.H. Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Cumberland Pharmaceuticals
  • Day Zero Diagnostics Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Glox Theraputics Ltd
  • Hikma Pharmaceuticals PLC
  • Innoviva, Inc.
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Novo Holdings A/S
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sandoz AG
  • Seres Therapeutics, Inc.
  • Shionogi & Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Wockhardt

Related Topics

Related Reports

Antibiotic Resistance Market Size, Share & Trends Analysis Report by Disease, Pathogen, Drug Class, Mechanism Of Action, Distribution Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Antibiotic Resistance Market Size, Share & Trends Analysis Report by Disease, Pathogen, Drug Class, Mechanism Of Action, Distribution Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Antibiotic Resistance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Antibiotic Resistance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 111 Pages
  • Global
From
Antibiotic Resistance Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Antibiotic Resistance Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 139 Pages
  • Global
From
Antibiotic Resistance Market Report 2026 - Product Image

Antibiotic Resistance Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Antibiotic Resistance Therapeutics Market 2025-2029 - Insights by Pathogen and Therapy Type, with Situation Analysis, Executive, and Investor Guides - Product Image

Antibiotic Resistance Therapeutics Market 2025-2029 - Insights by Pathogen and Therapy Type, with Situation Analysis, Executive, and Investor Guides

  • Report
  • 470 Pages
  • Global
From

About the Antimicrobial Resistance Market

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria. Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.